• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Delirium - Pipeline Review, H2 2012 Product Image

Delirium - Pipeline Review, H2 2012

  • ID: 2335234
  • November 2012
  • 32 pages
  • Global Markets Direct

Delirium – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Delirium - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Delirium, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Delirium. Delirium - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Delirium.
- A review of the Delirium products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Delirium Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Delirium 7
Delirium Therapeutics under Development by Companies 9
Delirium Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Delirium Therapeutics – Products under Development by Companies 14
Delirium Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Delirium Therapeutics Development 16
Gaia BioPharma Limited 16
Delirium – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
GAI-122 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
dexmedetomidine hydrochloride - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
donepezil hydrochloride - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
haloperidol - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ziprasidone hydrochloride - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Delirium Therapeutics – Drug Profile Updates 28
Delirium Therapeutics – Discontinued Products 29
Delirium Therapeutics - Dormant Products 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables
Number of Products Under Development for Delirium, H2 2012 7
Products under Development for Delirium – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Gaia BioPharma Limited, H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Delirium Therapeutics – Drug Profile Updates 28
Delirium Therapeutics – Discontinued Products 29
Delirium Therapeutics – Dormant Products 30

List of Figures
Number of Products under Development for Delirium, H2 2012 7
Products under Development for Delirium – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos